Experimental CAR t therapy for myeloma shows early promise but trial halted
Disease control
Terminated
This early-phase study tested a new treatment called Descartes-15 for people with multiple myeloma that had come back or stopped responding to other therapies. The treatment uses a patient's own immune cells, engineered with RNA to target cancer cells. Only 4 people were enrolled…
Phase: PHASE1 • Sponsor: Cartesian Therapeutics • Aim: Disease control
Last updated May 11, 2026 20:39 UTC